The aim of this study is to contribute to our understanding of HIV viral suppression in patients treated with DTG-based regimens and various other antiretroviral (ARV) regimens, and to identify associated factors. Methods: This is a descriptive cross-sectional study conducted at 15 HIV care sites (PEC) from February to March 2022. Viral loads (VL) in patients on ARV therapy were determined using Generic HIV (Biocentric?) kits and the Xpert HIV-1 Viral Load XC (GeneXpert?) test. Sociodemographic, therapeutic, and virological data were collected using a pre-designed questionnaire. Data processing and analysis were performed using Stata software. Observations with missing data were excluded. The significance level used for the multivariate analysis was 5%. Results: Of the 8852 expected HIV-positive individuals, 3259 (36.8%) had their viral load measured. Female patients were in the majority, with 1468 (98.4%) compared to 24 (1.6%) males. The 31- to 45-year-old age group was the largest compared to other age groups. The highest rates of viral suppression (VC < 1000 copies/mL) were observed with the combinations Tenofovir + Emtricitabine + Efavirenz (TDF + FTC + EFV) and Tenofovir + Lamivudine + Dolutegravir (TDF + 3TC + DTG), with identical results (85.1%). The best virological response was observed with the 2 NRTIs + 1 INIs (85.1%) and 2 NRTIs + 1 NNRTI (84.2%) regimens, and multivariate analysis of factors associated with viral suppression showed no significant difference between these two treatment regimens (p = 0.674). Conclusion: The ARV drug combinations used generally resulted in good viral load suppression. DTG is a good alternative to other ARV drugs in first-line ART.
References
[1]
Blouin, E., St-Amour, P., et al. (2023) L’essentiel du VIH 3e édition.
[2]
ANAIDS (2025) Fiche d’information 2025—Dernières statistiques sur l’état de l’épidémie de sida. https://www.unaids.org/fr/resources/documents/2025/UNAIDS_FactSheet
[3]
Morlat, P., et al. (2018) Prise en charge médicale des personnes vivant avec le VIH: Initiation d’un premier traitement antirétroviral. https://cns.sante.fr/sites/cns-sante/files/2017/01/experts-vih_initiation.pdf
[4]
Dinesha, T.R., Gomathi, S., Boobalan, J., Sivamalar, S., Solomon, S.S., Pradeep, A., et al. (2016) Genotypic HIV-1 Drug Resistance among Patients Failing Tenofovir-Based First-Line HAART in South India. AIDSResearchandHumanRetroviruses, 32, 1234-1236. https://doi.org/10.1089/aid.2016.0110
[5]
WHO (2017) Traitement du VIH: Transition vers de nouveaux antirétroviraux dans les programmes de lutte contre le VIH. https://medicinespatentpool.org/uploads/2017/07/Policy-brief-Transition-to-new-antiretroviral-drugs-in-HIV-programmes-fr-web.pdf
[6]
WHO (2021) Consolidated Guidelines on HIV Prevention, Testing, Treatment, Service Delivery and Monitoring: Recommendations for a Public Health Approach. https://iris.who.int/server/api/core/bitstreams/a4c03ed9-5446-4958-a26f-10e505c2679c/content
[7]
Mmatsoku, M.S. and Ngcobo, S. (2024) Factors Linked to Virological Failure in People on a Dolutegravir-Based Regimen in Mamelodi. SouthernAfricanJournalofInfectiousDiseases, 39, a670. https://doi.org/10.4102/sajid.v39i1.670
[8]
Ministère de la santé publique et de la prévention du Tchad (2022) Programme Sectoriel de lutte contre le Sida et les Infections sexuellement Transmissible (PSLS/IST). Rapport annuel 2022.
[9]
Abderrazzack, A.F. (2021) Le dolutégravir change la vie des personnes vivant avec le VIH au Tchad. Medecine Patent. https://medicinespatentpool.org/fr/story-post/hiv-prevalence-and-dtg-in-chad
[10]
Ota, R., Ishii, H., Tsuda, M., Higuchi, Y. and Yamashita, F. (2019) A Model-Based Comparative Meta-Analysis of the Efficacy of Dolutegravir-Based and Efavirenz-Based Regimens in HIV-Infected Patients. JournalofInfectionandChemotherapy, 25, 687-694. https://doi.org/10.1016/j.jiac.2019.03.015
[11]
Silva, G.J.D., Mendicino, C.C.P., Pádua, C.A.M.D. and Tupinambás, U. (2023) Suppression of HIV in the First 12 Months of Antiretroviral Therapy: A Comparative Analysis of Dolutegravir-and Efavirenz-Based Regimens. Einstein (S？oPaulo), 21, 1-10. https://doi.org/10.31744/einstein_journal/2023ao0156
[12]
Semengue, E.N.J., Fokam, J., Etame, N., Molimbou, E., Chenwi, C.A., Takou, D., et al. (2022) Dolutegravir-Based Regimen Ensures High Virological Success Despite Prior Exposure to Efavirenz-Based First-Line ART in Cameroon: An Evidence of a Successful Transition Model. Viruses, 15, Article 18. https://doi.org/10.3390/v15010018
[13]
Arora, S., Singh, D., Ashta, K., Kisenjang, N., Mohan, C., Anilkumar, A., et al. (2025) Virological Effectiveness of Dolutegravir-Based Second-Line ART in the Context of NRTI Resistance among HIV-Positive Patients in India. TheOpenAIDSJournal, 19, e18746136382073. https://doi.org/10.2174/0118746136382073250806110823
[14]
Veil, R., Poizot-Martin, I., Reynes, J., Goujard, C., Seng, R., Delobel, P., et al. (2020) Virological and Immunological Impact of Integrase Inhibitor-Based Regimens Initiated during Primary HIV-1 Infection. AIDS, 34, 493-500. https://doi.org/10.1097/qad.0000000000002447
[15]
Mynthlu, F., Jeetenkumar Singh, T., Tlau, L. and Bhutia, A. (2024) Immunovirological Response and Adverse Effects of Dolutegravir-Based Regimen in People Living with HIV/AIDS. Journal of Medical Society, 30, 50-56.
[16]
BIOCENTRIC (2021) Generic HIV Charge Virale. Test d’amplification des acides nucléiques pour la quantification du virus VIH-1.
WHO (2014) Considérations techniques et opérationnelles pour la mise en ？uvre de la mesure de la charge virale du VIH: Accès aux produits diagnostiques du VIH. https://iris.who.int/bitstream/handle/10665/275371/9789242507577-fre.pdf
[19]
Zhong, M., Li, M., Qi, M., Su, Y., Yu, N., Lv, R., et al. (2023) A Retrospective Clinical Study of Dolutegravir-versus Efavirenz-Based Regimen in Treatment-Na？ve Patients with Advanced HIV Infection in Nanjing, China. FrontiersinImmunology, 13, Article 1033098. https://doi.org/10.3389/fimmu.2022.1033098
[20]
Gado, A.M., Daou, M., Malam, B.M., Maidakouale, C., Moussa, B.O.R., Moussa, S.S., Yacouba, N., Adehossi, E. and Ndour, C. (2022) évolution Immuno-Virologique des Per-sonnes Vivant avec le Virus d’Immunodéficience Humaine sous Traitement Anti-rétroviral Incarcérées à la Maison d’Arrêt de Niamey. Health Sciences and Disease, 23, 61-66.
[21]
Telly, N., Kamian, M., Sangho, O., Kayentao, K., Berthé, M., Coulibaly, C.A., et al. (2022) Facteurs Associés à l’échec du Traitement VIH au Centre Hospitalier Universitaire du Point G, Bamako. Health Sciences and Disease, 23, 75-80. https://www.hsd-fmsb.org/index.php/hsd/article/view/3882
[22]
Ayal, M.A. and Berha, A.B. (2023) Comparative Safety and Changes in Immunologic and Virologic Parameters of Dolutegravir versus Efavirenz-Based Antiretroviral Therapies among HIV Patients: A Retrospective Cohort Study. HIV/AIDS—Research and Palliative Care, 15, 173-190. https://doi.org/10.2147/hiv.s396420
[23]
Dorward, J., Sookrajh, Y., Khubone, T., van der Molen, J., Govender, R., Phakathi, S., et al. (2023) Implementation and Outcomes of Dolutegravir-Based First-Line Antiretroviral Therapy for People with HIV in South Africa: A Retrospective Cohort Study. TheLancetHIV, 10, e284-e294. https://doi.org/10.1016/s2352-3018(23)00047-4
[24]
Oscar, A.F., Amedé, N.K., Ahmat, A.M., Franklin, D., Djelani, O.A., Foulzi, M., et al. (2024) Prevalence of Residual Replication in HIV-1 Patients on Tenofovir, Lamuvidine and Dolutegravir (TLD) Treatment Followed at Al-Nadjma Multipurpose Center from 2021 to 2023. InternationalJournalofLifeScienceResearchArchive, 6, 148-154. https://doi.org/10.53771/ijlsra.2024.6.1.0042
[25]
Kone, F., Toni, T.D., Ouassa, T., Menan, H., Ebegui, D., Diallo, K., et al. (2019) Mesure de l’ARN VIH-1 et du taux de lymphocytes TCD4 dans le suivi du traitement antirétroviral de patients infectés par le VIH en C？te d’Ivoire. InternationalJournalofBiologicalandChemicalSciences, 13, 1343-1353. https://doi.org/10.4314/ijbcs.v13i3.11
[26]
Correa, A., Monteiro, P., Calixto, F., Batista, J.D.L., de Alencar Ximenes, R.A. and Montarroyos, U.R. (2020) Dolutegravir: Virologic Response and Tolerability of Initial Antiretroviral Regimens for Adults Living with HIV. PLOSONE, 15, e0238052. https://doi.org/10.1371/journal.pone.0238052
[27]
Kouanfack, C., Mpoudi-Etame, M., Bassega, P.O., Eymard-Duvernay, S., Leroy, S., Boyer, S., Peeters, M., Calmy, A. and Delaporte, E. (2024) Dolutegravir or Low Dose of Efavirenz-Based Regimen for the Initial Treatment of HIV-1 Infection. NewEnglandJournalofMedicine, 381, 816-826. https://www.nejm.org/doi/full/10.1056/NEJMoa1904340
[28]
Devendra, A., Kohler, M., Letsika, M., Khooa, H., Motaboli, L., Lerotholi, M., et al. (2024) HIV Viral Suppression in Children and Adolescents 2 Years after Transition to Dolutegravir: A Multicentre Cohort Study. AIDS, 38, 1013-1023. https://doi.org/10.1097/qad.0000000000003835
[29]
Coulibaly, Y.A., Ma？ga, A.I., Coulibaly, Y.I., Telly, N., Sangaré, A., Sacko, K., et al. (2023) Factors Associated with Viral Load Suppression in Adolescents on Highly Active Antiretroviral Therapy in Mali. Health Sciences and Disease, 24, 1-7.
[30]
Sterling, T.R., Vlahov, D., Astemborski, J., Hoover, D.R., Margolick, J.B. and Quinn, T.C. (2001) Initial Plasma HIV-1 RNA Levels and Progression to AIDS in Women and Men. NewEnglandJournalofMedicine, 344, 720-725. https://doi.org/10.1056/nejm200103083441003
[31]
AFRAVIH (2024) Traiter l’infection VIH: Les médicaments antirétroviraux. APRAPEDIA. https://www.afrapedia.org/vih/arv
[32]
Riddler, S.A., Haubrich, R., DiRienzo, A.G., Peeples, L., Powderly, W.G., Klingman, K.L., et al. (2008) Class-Sparing Regimens for Initial Treatment of HIV-1 Infection. NewEnglandJournalofMedicine, 358, 2095-2106. https://doi.org/10.1056/nejmoa074609
[33]
Gouvernement du Québec (202) La thérapie antirétrovirale pour les adultes infectés par le VIH: Guide pour les professionnels de la santé. La Direction des communications du ministère de la Santé et des Services sociaux. https://publications.msss.gouv.qc.ca/msss/document-000733/
